1. Home
  2. VRAX vs PRPO Comparison

VRAX vs PRPO Comparison

Compare VRAX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • PRPO
  • Stock Information
  • Founded
  • VRAX 2013
  • PRPO N/A
  • Country
  • VRAX United Kingdom
  • PRPO United States
  • Employees
  • VRAX N/A
  • PRPO N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • VRAX Health Care
  • PRPO Industrials
  • Exchange
  • VRAX Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • VRAX 7.3M
  • PRPO 9.9M
  • IPO Year
  • VRAX 2022
  • PRPO N/A
  • Fundamental
  • Price
  • VRAX $1.66
  • PRPO $6.65
  • Analyst Decision
  • VRAX
  • PRPO
  • Analyst Count
  • VRAX 0
  • PRPO 0
  • Target Price
  • VRAX N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • VRAX 256.7K
  • PRPO 6.8K
  • Earning Date
  • VRAX 02-05-2025
  • PRPO 03-28-2025
  • Dividend Yield
  • VRAX N/A
  • PRPO N/A
  • EPS Growth
  • VRAX N/A
  • PRPO N/A
  • EPS
  • VRAX N/A
  • PRPO N/A
  • Revenue
  • VRAX $84,872.00
  • PRPO $17,411,000.00
  • Revenue This Year
  • VRAX $5,169.18
  • PRPO $75.18
  • Revenue Next Year
  • VRAX $66.97
  • PRPO N/A
  • P/E Ratio
  • VRAX N/A
  • PRPO N/A
  • Revenue Growth
  • VRAX 7.03
  • PRPO 31.31
  • 52 Week Low
  • VRAX $0.60
  • PRPO $4.31
  • 52 Week High
  • VRAX $9.00
  • PRPO $7.20
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 42.25
  • PRPO 63.80
  • Support Level
  • VRAX $1.56
  • PRPO $6.52
  • Resistance Level
  • VRAX $1.86
  • PRPO $6.90
  • Average True Range (ATR)
  • VRAX 0.19
  • PRPO 0.27
  • MACD
  • VRAX -0.04
  • PRPO 0.03
  • Stochastic Oscillator
  • VRAX 26.31
  • PRPO 89.90

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: